ABSTRACT
Clinical trial emulation, which is the process of mimicking targeted randomized controlled trials (RCT) with real world data (RWD), has attracted growing attentions and interests in recent years from pharmaceutical industry. Different from RCTs which have stringent eligibility criteria for recruiting participants, RWD are more representative of real world patients whom the drugs will be prescribed to. One technical challenge for trial emulation is how to conduct effective confounding control with complex RWD so that the treatment effects can be objectively derived. Recently many approaches, including deep learning algorithms, have been proposed for this goal, but there is still no systematic evaluation and practical guidance on them. In this paper, we emulate 430,000 trials from two large-scale RWD warehouses, covering both electronic health records (EHR) and general claims, over 170 million patients spanning more than 10 years, aiming to identify new indications of approved drugs for Alzheimer’s disease (AD). We have investigated the behaviors of multiple different approaches including logistic regression and deep learning models, and propose a new model selection strategy that can significantly improve the performance of confounding balance of the participants in different arms of emulated trials. We demonstrate that regularized logistic regression based propensity score (PS) model outperforms deep learning based PS model and others, which contradicts with our intuitions to certain extent. Finally, we identified 8 drugs whose original indications are not AD (pantoprazole, gabapentin, acetaminophen, atorvastatin, albuterol, fluticasone, amoxicillin and omeprazole), hold great potential of being beneficial to AD patients.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The work of C.Z., H.Z. and F.W. were supported by NIH awards R01MH124740 and RF1AG072449, as well as NSF award 1750326. B.S.G. is supported by NIH grant RF1AG059319. J.B. is supported by NIH awards R21AG068717, R56AG069880, R01CA246418-02S1, and R21CA245858-01A1S1.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Use of the de-identified databases--OneFlorida Clinical Research Consortium and IBM {MarketScan} Commercial Claims and Encounters--was approved by the Institutional Review Board of Weill Cornell Medicine, New York, NY. The use of OneFlorida data for this study is approved under the University of Florida IRB number IRB202001888. Access to the MarketScan data analyzed in this manuscript is provided by the University of Kentucky.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
OneFlorida data can be requested through \url{https://onefloridaconsortium.org/front-door/}. Since OneFlorida data is a HIPAA-limited data set, a data use agreement needs to be established with the OneFlorida network.The MarketScan dataset is available from IBM at \url{https://www.ibm.com/products/marketscan-research-databases}.
